2025年11月18日周二，Revvity Inc. (NYSE:RVTY)参加了2025年杰富瑞伦敦医疗保健会议，展示了一系列喜忧参半的战略洞察。公司报告第三季度实现了1%的有机增长，其中生命科学部门面临挑战，而诊断业务则表现出良好势头。尽管学术和政府部门预算受限，Revvity仍概述了其未来增长战略，包括专注于软件和仪器设备。

Where to go in 2026, according to Travel + Leisure editors—for the food, culture, nature, adventure, and more.

This study provides valuable data on the role of Hsd17b7, a gene involved in cholesterol biosynthesis, as a potential regulator of mechanosensory hair cell function. The authors used both zebrafish ...